TLSA — Tiziana Life Sciences Cashflow Statement
0.000.00%
- $211.51m
- $204.36m
Annual cashflow statement for Tiziana Life Sciences, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | ARS | 20-F | 20-F | 20-F | 20-F |
| Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
| Status: | fx Final | Final | Final | Final | Final |
| Net Income/Starting Line | -28.3 | -26.7 | -15.4 | -17.2 | -16.7 |
| Depreciation | |||||
| Non-Cash Items | 16.6 | 4.11 | -3.6 | 3.03 | 6.86 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | -0.294 | 0.642 | -0.674 | -1.58 | 8.23 |
| Change in Accounts Receivable | |||||
| Change in Accounts Payable | |||||
| Change in Payable / Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Other Operating Cash Flow | |||||
| Cash from Operating Activities | -11.9 | -21.8 | -19.6 | -15.7 | -1.53 |
| Capital Expenditures | -0.127 | -0.022 | 0 | — | -0.019 |
| Purchase of Fixed Assets | |||||
| Purchase / Acquisition of Intangibles | |||||
| Other Investing Cash Flow Items | — | 0.152 | -4 | -1.25 | -0.052 |
| Purchase of Investments | |||||
| Other Investing Cash Flow | |||||
| Cash from Investing Activities | -0.127 | 0.13 | -4 | -1.25 | -0.071 |
| Financing Cash Flow Items | -4.02 | — | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 73.7 | -0.023 | -0.055 | 0.04 | 4.5 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 61.6 | -23.6 | -24.1 | -16.9 | 2.54 |